David Chang, Allogene CEO (Credit: Jeff Rumans)

Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Al­lo­gene Ther­a­peu­tics is switch­ing up clin­i­cal plans for its off-the-shelf CAR-T ther­a­pies. In a bid to leapfrog more es­tab­lished ri­vals, the South San Fran­cis­co biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.